Paradigm posts positive Phase II trial results on iPPS in osteoarthritis

Australian drug developer Paradigm Biopharmaceuticals (ASX PAR) saw its shares gain 4% to A$1.27 in early trading, as it announced that analysis of six-month trial data shows injectable pentosan polysulfate sodium (iPPS) may slow the progression of osteoarthritis of the knee.

In October 2022, Paradigm said its Phase II clinical study met its primary endpoint of a change from baseline to day 56 in one or more osteoarthritis disease biomarkers in synovial fluid.

In addition to reaching the primary endpoint, clinical scores using the Western Ontario McMaster Universities Arthritis Index (WOMAC) of pain and function at day 56 were statistically significant. The change from baseline to day 56 for pain and function are the approved endpoints in Paradigm’s 300-patient global Phase III trial currently recruiting in the US, Europe and Australia.